PUBLISHER: Global Insight Services | PRODUCT CODE: 2108290
PUBLISHER: Global Insight Services | PRODUCT CODE: 2108290
CRISPR Based Gene Therapies Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Process, End User, Solutions, Stage
The global CRISPR Based Gene Therapies Market is projected to grow from $3.2 billion in 2025 to $9.0 billion by 2035, at a compound annual growth rate (CAGR) of 10.8%. Growth is driven by advancements in gene editing technology, increased funding for genetic research, and rising prevalence of genetic disorders necessitating innovative therapeutic solutions. The CRISPR Based Gene Therapies Market exhibits a moderately consolidated competitive landscape, led by oncology therapies, followed by treatments for rare genetic disorders and infectious diseases. The market is driven by expanding applications in both in vivo and ex vivo gene editing, supported by continuous advancements in CRISPR technology. Increasing clinical research, regulatory progress, and growing investment in gene therapy are accelerating market development. Competition is shaped by established pharmaceutical companies, biotechnology firms, and emerging innovators focused on improving editing precision and safety. Strategic partnerships, research collaborations, and licensing agreements with academic institutions are fostering innovation, strengthening product pipelines, and supporting the commercialization of next-generation CRISPR-based therapies.
Based on Technology, the market is segmented into CRISPR/Cas9, CRISPR/Cpf1, CRISPR/Cas12a, CRISPR/Cas13, and Others. Among these, CRISPR/Cas9 accounts for the largest share of the CRISPR-based gene therapies market due to its high editing efficiency, ease of design, and extensive validation across research and therapeutic applications. It is widely used for developing treatments for genetic disorders, cancer, and rare diseases, supported by a strong pipeline of clinical programs. Meanwhile, CRISPR/Cas12a and CRISPR/Cas13 are gaining traction because of their unique targeting capabilities, improved specificity, and expanding applications in gene editing and RNA-targeted therapeutics, contributing to future market growth.
| Market Segmentation | |
|---|---|
| Type | In Vivo, Ex Vivo, Others |
| Product | CRISPR Enzymes, CRISPR Libraries, CRISPR Kits, Others |
| Services | Gene Editing Services, Custom CRISPR Services, Consultation Services, Others |
| Technology | CRISPR/Cas9, CRISPR/Cpf1, CRISPR/Cas12a, CRISPR/Cas13, Others |
| Application | Cancer Therapy, Rare Diseases, Genetic Disorders, Cardiovascular Diseases, Infectious Diseases, Others |
| Process | Gene Knockout, Gene Knock-In, Gene Activation, Gene Repression, Others |
| End User | Biotechnology Companies, Pharmaceutical Companies, Academic & Research Institutes, Contract Research Organizations, Others |
| Solutions | Therapeutic Solutions, Research Solutions, Diagnostic Solutions, Others |
| Stage | Discovery, Preclinical, Clinical Trials, Commercialization, Others |
Based on Application, the market is segmented into Cancer Therapy, Rare Diseases, Genetic Disorders, Cardiovascular Diseases, Infectious Diseases, and Others. Among these, Genetic Disorders represent the largest segment owing to the growing focus on developing one-time curative therapies for inherited diseases such as sickle cell disease, beta-thalassemia, and Duchenne muscular dystrophy. Increasing clinical success, regulatory support, and investment in gene-editing research continue to drive this segment. Cancer Therapy is also witnessing rapid growth as CRISPR technologies are increasingly utilized for engineering immune cells, improving cell-based therapies, and enabling precision oncology approaches for both hematological and solid tumors.
Geographical Overview
North America holds the largest share of the CRISPR-based gene therapies market due to its well-established biotechnology sector, robust clinical research ecosystem, and significant investments in gene-editing technologies. The presence of leading biotechnology companies, academic research centers, and pharmaceutical firms has accelerated the development of CRISPR-based therapies for rare genetic disorders, cancer, and inherited diseases. Strong government funding, favorable regulatory frameworks for clinical research, and active collaborations between industry and research institutions further support market expansion. Continuous innovation, increasing clinical trial activity, and high healthcare expenditure reinforce North America's leadership in the global market.
Asia-Pacific is projected to be the fastest-growing market for CRISPR-based gene therapies, driven by increasing investments in biotechnology research, expanding genomic medicine programs, and improving healthcare infrastructure. China, Japan, South Korea, and Singapore are actively promoting gene-editing research through government initiatives and public-private partnerships. Rising prevalence of genetic diseases, growing clinical trial activities, and increasing demand for precision medicine are accelerating market growth. Expanding biotechnology startups, favorable research funding, and international collaborations are strengthening innovation capabilities, positioning Asia-Pacific as the fastest-growing regional market for CRISPR-based gene therapies.
Key Trends and Drivers
Expansion of Next-Generation CRISPR Platforms Is Advancing Gene Therapy Development:
The development of advanced CRISPR technologies, including base editing, prime editing, and multiplex gene editing, is a major trend in the CRISPR based gene therapies market. These next-generation platforms enable highly precise genetic modifications with improved safety and reduced off-target effects. Researchers are increasingly exploring in vivo gene editing and novel delivery systems such as lipid nanoparticles to expand therapeutic applications. The growing number of clinical trials targeting rare diseases, cancer, blood disorders, and inherited conditions is further accelerating innovation and strengthening the clinical potential of CRISPR-based therapies.
Rising Burden of Genetic Diseases Is Driving the Market Growth:
The increasing prevalence of inherited genetic disorders and rare diseases is a key driver of the CRISPR based gene therapies market. Conventional treatment approaches often provide only symptomatic relief, creating strong demand for therapies capable of correcting disease-causing genetic mutations. Growing investments in biotechnology research, supportive regulatory pathways for advanced therapies, increasing clinical trial activity, and expanding collaborations between academic institutions and pharmaceutical companies are accelerating product development and commercialization, contributing significantly to global market growth.
Research Scope
- Estimates and forecasts the overall market size across type, application, and region.
- Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
- Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
- Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
- Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
- Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
- Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.
Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.
TABLE OF CONTENTS
1 Executive Summary
- 1.1 Market Size and Forecast
- 1.2 Market Overview
- 1.3 Market Snapshot
- 1.4 Regional Snapshot
- 1.5 Strategic Recommendations
- 1.6 Analyst Notes
2 Market Highlights
- 2.1 Key Market Highlights by Type
- 2.2 Key Market Highlights by Product
- 2.3 Key Market Highlights by Services
- 2.4 Key Market Highlights by Technology
- 2.5 Key Market Highlights by Application
- 2.6 Key Market Highlights by End User
- 2.7 Key Market Highlights by Process
- 2.8 Key Market Highlights by Solutions
- 2.9 Key Market Highlights by Stage
3 Market Dynamics
- 3.1 Macroeconomic Analysis
- 3.2 Market Trends
- 3.3 Market Drivers
- 3.4 Market Opportunities
- 3.5 Market Restraints
- 3.6 CAGR Growth Analysis
- 3.7 Impact Analysis
- 3.8 Emerging Markets
- 3.9 Technology Roadmap
- 3.10 Strategic Frameworks
- 3.10.1 PORTER's 5 Forces Model
- 3.10.2 ANSOFF Matrix
- 3.10.3 4P's Model
- 3.10.4 PESTEL Analysis
4 Segment Analysis
- 4.1 Market Size & Forecast by Type (2020-2035)
- 4.1.1 In Vivo
- 4.1.2 Ex Vivo
- 4.1.3 Others
- 4.2 Market Size & Forecast by Product (2020-2035)
- 4.2.1 CRISPR Enzymes
- 4.2.2 CRISPR Libraries
- 4.2.3 CRISPR Kits
- 4.2.4 Others
- 4.3 Market Size & Forecast by Services (2020-2035)
- 4.3.1 Gene Editing Services
- 4.3.2 Custom CRISPR Services
- 4.3.3 Consultation Services
- 4.3.4 Others
- 4.4 Market Size & Forecast by Technology (2020-2035)
- 4.4.1 CRISPR/Cas9
- 4.4.2 CRISPR/Cpf1
- 4.4.3 CRISPR/Cas12a
- 4.4.4 CRISPR/Cas13
- 4.4.5 Others
- 4.5 Market Size & Forecast by Application (2020-2035)
- 4.5.1 Cancer Therapy
- 4.5.2 Rare Diseases
- 4.5.3 Genetic Disorders
- 4.5.4 Cardiovascular Diseases
- 4.5.5 Infectious Diseases
- 4.5.6 Others
- 4.6 Market Size & Forecast by End User (2020-2035)
- 4.6.1 Biotechnology Companies
- 4.6.2 Pharmaceutical Companies
- 4.6.3 Academic & Research Institutes
- 4.6.4 Contract Research Organizations
- 4.6.5 Others
- 4.7 Market Size & Forecast by Process (2020-2035)
- 4.7.1 Gene Knockout
- 4.7.2 Gene Knock-In
- 4.7.3 Gene Activation
- 4.7.4 Gene Repression
- 4.7.5 Others
- 4.8 Market Size & Forecast by Solutions (2020-2035)
- 4.8.1 Therapeutic Solutions
- 4.8.2 Research Solutions
- 4.8.3 Diagnostic Solutions
- 4.8.4 Others
- 4.9 Market Size & Forecast by Stage (2020-2035)
- 4.9.1 Discovery
- 4.9.2 Preclinical
- 4.9.3 Clinical Trials
- 4.9.4 Commercialization
- 4.9.5 Others
5 Regional Analysis
- 5.1 Global Market Overview
- 5.2 North America Market Size (2020-2035)
- 5.2.1 United States
- 5.2.1.1 Type
- 5.2.1.2 Product
- 5.2.1.3 Services
- 5.2.1.4 Technology
- 5.2.1.5 Application
- 5.2.1.6 End User
- 5.2.1.7 Process
- 5.2.1.8 Solutions
- 5.2.1.9 Stage
- 5.2.2 Canada
- 5.2.2.1 Type
- 5.2.2.2 Product
- 5.2.2.3 Services
- 5.2.2.4 Technology
- 5.2.2.5 Application
- 5.2.2.6 End User
- 5.2.2.7 Process
- 5.2.2.8 Solutions
- 5.2.2.9 Stage
- 5.2.3 Mexico
- 5.2.3.1 Type
- 5.2.3.2 Product
- 5.2.3.3 Services
- 5.2.3.4 Technology
- 5.2.3.5 Application
- 5.2.3.6 End User
- 5.2.3.7 Process
- 5.2.3.8 Solutions
- 5.2.3.9 Stage
- 5.2.1 United States
- 5.3 Latin America Market Size (2020-2035)
- 5.3.1 Brazil
- 5.3.1.1 Type
- 5.3.1.2 Product
- 5.3.1.3 Services
- 5.3.1.4 Technology
- 5.3.1.5 Application
- 5.3.1.6 End User
- 5.3.1.7 Process
- 5.3.1.8 Solutions
- 5.3.1.9 Stage
- 5.3.2 Argentina
- 5.3.2.1 Type
- 5.3.2.2 Product
- 5.3.2.3 Services
- 5.3.2.4 Technology
- 5.3.2.5 Application
- 5.3.2.6 End User
- 5.3.2.7 Process
- 5.3.2.8 Solutions
- 5.3.2.9 Stage
- 5.3.3 Rest of Latin America
- 5.3.3.1 Type
- 5.3.3.2 Product
- 5.3.3.3 Services
- 5.3.3.4 Technology
- 5.3.3.5 Application
- 5.3.3.6 End User
- 5.3.3.7 Process
- 5.3.3.8 Solutions
- 5.3.3.9 Stage
- 5.3.1 Brazil
- 5.4 Asia-Pacific Market Size (2020-2035)
- 5.4.1 China
- 5.4.1.1 Type
- 5.4.1.2 Product
- 5.4.1.3 Services
- 5.4.1.4 Technology
- 5.4.1.5 Application
- 5.4.1.6 End User
- 5.4.1.7 Process
- 5.4.1.8 Solutions
- 5.4.1.9 Stage
- 5.4.2 India
- 5.4.2.1 Type
- 5.4.2.2 Product
- 5.4.2.3 Services
- 5.4.2.4 Technology
- 5.4.2.5 Application
- 5.4.2.6 End User
- 5.4.2.7 Process
- 5.4.2.8 Solutions
- 5.4.2.9 Stage
- 5.4.3 South Korea
- 5.4.3.1 Type
- 5.4.3.2 Product
- 5.4.3.3 Services
- 5.4.3.4 Technology
- 5.4.3.5 Application
- 5.4.3.6 End User
- 5.4.3.7 Process
- 5.4.3.8 Solutions
- 5.4.3.9 Stage
- 5.4.4 Japan
- 5.4.4.1 Type
- 5.4.4.2 Product
- 5.4.4.3 Services
- 5.4.4.4 Technology
- 5.4.4.5 Application
- 5.4.4.6 End User
- 5.4.4.7 Process
- 5.4.4.8 Solutions
- 5.4.4.9 Stage
- 5.4.5 Australia
- 5.4.5.1 Type
- 5.4.5.2 Product
- 5.4.5.3 Services
- 5.4.5.4 Technology
- 5.4.5.5 Application
- 5.4.5.6 End User
- 5.4.5.7 Process
- 5.4.5.8 Solutions
- 5.4.5.9 Stage
- 5.4.6 Taiwan
- 5.4.6.1 Type
- 5.4.6.2 Product
- 5.4.6.3 Services
- 5.4.6.4 Technology
- 5.4.6.5 Application
- 5.4.6.6 End User
- 5.4.6.7 Process
- 5.4.6.8 Solutions
- 5.4.6.9 Stage
- 5.4.7 Rest of APAC
- 5.4.7.1 Type
- 5.4.7.2 Product
- 5.4.7.3 Services
- 5.4.7.4 Technology
- 5.4.7.5 Application
- 5.4.7.6 End User
- 5.4.7.7 Process
- 5.4.7.8 Solutions
- 5.4.7.9 Stage
- 5.4.1 China
- 5.5 Europe Market Size (2020-2035)
- 5.5.1 Germany
- 5.5.1.1 Type
- 5.5.1.2 Product
- 5.5.1.3 Services
- 5.5.1.4 Technology
- 5.5.1.5 Application
- 5.5.1.6 End User
- 5.5.1.7 Process
- 5.5.1.8 Solutions
- 5.5.1.9 Stage
- 5.5.2 France
- 5.5.2.1 Type
- 5.5.2.2 Product
- 5.5.2.3 Services
- 5.5.2.4 Technology
- 5.5.2.5 Application
- 5.5.2.6 End User
- 5.5.2.7 Process
- 5.5.2.8 Solutions
- 5.5.2.9 Stage
- 5.5.3 United Kingdom
- 5.5.3.1 Type
- 5.5.3.2 Product
- 5.5.3.3 Services
- 5.5.3.4 Technology
- 5.5.3.5 Application
- 5.5.3.6 End User
- 5.5.3.7 Process
- 5.5.3.8 Solutions
- 5.5.3.9 Stage
- 5.5.4 Spain
- 5.5.4.1 Type
- 5.5.4.2 Product
- 5.5.4.3 Services
- 5.5.4.4 Technology
- 5.5.4.5 Application
- 5.5.4.6 End User
- 5.5.4.7 Process
- 5.5.4.8 Solutions
- 5.5.4.9 Stage
- 5.5.5 Italy
- 5.5.5.1 Type
- 5.5.5.2 Product
- 5.5.5.3 Services
- 5.5.5.4 Technology
- 5.5.5.5 Application
- 5.5.5.6 End User
- 5.5.5.7 Process
- 5.5.5.8 Solutions
- 5.5.5.9 Stage
- 5.5.6 Rest of Europe
- 5.5.6.1 Type
- 5.5.6.2 Product
- 5.5.6.3 Services
- 5.5.6.4 Technology
- 5.5.6.5 Application
- 5.5.6.6 End User
- 5.5.6.7 Process
- 5.5.6.8 Solutions
- 5.5.6.9 Stage
- 5.5.1 Germany
- 5.6 Middle East & Africa Market Size (2020-2035)
- 5.6.1 Saudi Arabia
- 5.6.1.1 Type
- 5.6.1.2 Product
- 5.6.1.3 Services
- 5.6.1.4 Technology
- 5.6.1.5 Application
- 5.6.1.6 End User
- 5.6.1.7 Process
- 5.6.1.8 Solutions
- 5.6.1.9 Stage
- 5.6.2 United Arab Emirates
- 5.6.2.1 Type
- 5.6.2.2 Product
- 5.6.2.3 Services
- 5.6.2.4 Technology
- 5.6.2.5 Application
- 5.6.2.6 End User
- 5.6.2.7 Process
- 5.6.2.8 Solutions
- 5.6.2.9 Stage
- 5.6.3 South Africa
- 5.6.3.1 Type
- 5.6.3.2 Product
- 5.6.3.3 Services
- 5.6.3.4 Technology
- 5.6.3.5 Application
- 5.6.3.6 End User
- 5.6.3.7 Process
- 5.6.3.8 Solutions
- 5.6.3.9 Stage
- 5.6.4 Sub-Saharan Africa
- 5.6.4.1 Type
- 5.6.4.2 Product
- 5.6.4.3 Services
- 5.6.4.4 Technology
- 5.6.4.5 Application
- 5.6.4.6 End User
- 5.6.4.7 Process
- 5.6.4.8 Solutions
- 5.6.4.9 Stage
- 5.6.5 Rest of MEA
- 5.6.5.1 Type
- 5.6.5.2 Product
- 5.6.5.3 Services
- 5.6.5.4 Technology
- 5.6.5.5 Application
- 5.6.5.6 End User
- 5.6.5.7 Process
- 5.6.5.8 Solutions
- 5.6.5.9 Stage
- 5.6.1 Saudi Arabia
6 Market Strategy
- 6.1 Demand-Supply Gap Analysis
- 6.2 Trade & Logistics Constraints
- 6.3 Price-Cost-Margin Trends
- 6.4 Market Penetration
- 6.5 Consumer Analysis
- 6.6 Regulatory Snapshot
7 Competitive Intelligence
- 7.1 Market Positioning
- 7.2 Market Share
- 7.3 Competition Benchmarking
- 7.4 Top Company Strategies
8 Company Profiles
- 8.1 Editas Medicine
- 8.1.1 Overview
- 8.1.2 Product Summary
- 8.1.3 Financial Performance
- 8.1.4 SWOT Analysis
- 8.2 CRISPR Therapeutics
- 8.2.1 Overview
- 8.2.2 Product Summary
- 8.2.3 Financial Performance
- 8.2.4 SWOT Analysis
- 8.3 Intellia Therapeutics
- 8.3.1 Overview
- 8.3.2 Product Summary
- 8.3.3 Financial Performance
- 8.3.4 SWOT Analysis
- 8.4 Beam Therapeutics
- 8.4.1 Overview
- 8.4.2 Product Summary
- 8.4.3 Financial Performance
- 8.4.4 SWOT Analysis
- 8.5 Caribou Biosciences
- 8.5.1 Overview
- 8.5.2 Product Summary
- 8.5.3 Financial Performance
- 8.5.4 SWOT Analysis
- 8.6 Sangamo Therapeutics
- 8.6.1 Overview
- 8.6.2 Product Summary
- 8.6.3 Financial Performance
- 8.6.4 SWOT Analysis
- 8.7 Precision BioSciences
- 8.7.1 Overview
- 8.7.2 Product Summary
- 8.7.3 Financial Performance
- 8.7.4 SWOT Analysis
- 8.8 Graphite Bio
- 8.8.1 Overview
- 8.8.2 Product Summary
- 8.8.3 Financial Performance
- 8.8.4 SWOT Analysis
- 8.9 Verve Therapeutics
- 8.9.1 Overview
- 8.9.2 Product Summary
- 8.9.3 Financial Performance
- 8.9.4 SWOT Analysis
- 8.10 Mammoth Biosciences
- 8.10.1 Overview
- 8.10.2 Product Summary
- 8.10.3 Financial Performance
- 8.10.4 SWOT Analysis
- 8.11 Cellectis
- 8.11.1 Overview
- 8.11.2 Product Summary
- 8.11.3 Financial Performance
- 8.11.4 SWOT Analysis
- 8.12 Horizon Discovery
- 8.12.1 Overview
- 8.12.2 Product Summary
- 8.12.3 Financial Performance
- 8.12.4 SWOT Analysis
- 8.13 Poseida Therapeutics
- 8.13.1 Overview
- 8.13.2 Product Summary
- 8.13.3 Financial Performance
- 8.13.4 SWOT Analysis
- 8.14 Arbor Biotechnologies
- 8.14.1 Overview
- 8.14.2 Product Summary
- 8.14.3 Financial Performance
- 8.14.4 SWOT Analysis
- 8.15 eGenesis
- 8.15.1 Overview
- 8.15.2 Product Summary
- 8.15.3 Financial Performance
- 8.15.4 SWOT Analysis
- 8.16 Inscripta
- 8.16.1 Overview
- 8.16.2 Product Summary
- 8.16.3 Financial Performance
- 8.16.4 SWOT Analysis
- 8.17 Synthego
- 8.17.1 Overview
- 8.17.2 Product Summary
- 8.17.3 Financial Performance
- 8.17.4 SWOT Analysis
- 8.18 Pairwise Plants
- 8.18.1 Overview
- 8.18.2 Product Summary
- 8.18.3 Financial Performance
- 8.18.4 SWOT Analysis
- 8.19 Tessera Therapeutics
- 8.19.1 Overview
- 8.19.2 Product Summary
- 8.19.3 Financial Performance
- 8.19.4 SWOT Analysis
- 8.20 Locus Biosciences
- 8.20.1 Overview
- 8.20.2 Product Summary
- 8.20.3 Financial Performance
- 8.20.4 SWOT Analysis
9 About Us
- 9.1 About Us
- 9.2 Research Methodology
- 9.3 Research Workflow
- 9.4 Consulting Services
- 9.5 Our Clients
- 9.6 Client Testimonials
- 9.7 Contact Us
